ABK Biomedical Announce First in Human Study Initiation

Patients will receive a single Eye90 microspheres™ radioembolization treatment with follow-up visits for one year to assess safety, effectiveness, and quality of life measures.

Scientific Excellence


ABK affiliated researchers recently presented new data at the Global Embolization Symposium & Technologies (GEST) annual online meeting.

Dr. Sam Miller, NC State University, received the “Best of GEST” Grand Prize for his oral presentation on a novel hepatic tumor microvascular model for evaluating Y90 Microspheres.

ABK Biomedical

Improving treatment options for patients with hypervascular liver tumors

Research and Development

Read about our Research & Development, including our multi-year strategic partnership with the Missouri University Research Reactor (MURR®). Operating at 10-megawatts, MURR is the most powerful research reactor in the United States.

Watch how we are developing novel Y90 radioembolization technologies to treat liver cancers.

Latest News

November 1st 2021

ABK Biomedical Announces Enrollment Initiation of First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors

Go to the Press Release»»

July 31st 2021

ABK Biomedical Affiliated Researchers Awarded “Best of GEST” Grand Prize for “Novel Hepatic Tumor Microvascular Model” Presentation at the 2021 Global Embolization Symposium Technologies Virtual Annual Meeting

Go to Scientific Presentations»»

July 31st 2021

ABK Biomedical Affiliated Researchers Present “CT Based Dosimetry in Y90 Radioembolization” during “Best of GEST” Session at the 2021 Global Embolization Symposium Technologies Virtual Annual Meeting

Go to Scientific Presentations»»

Company News & Press Releases

ABK and University of Missouri Veterinary Health Center partner on new Y90 liver cancer trial for dogs

Halifax, Nova Scotia. March 7th, 2021. ABK Biomedical today announced that they entered into a partnership with…

Read about the study»»

ABK Biomedical partners with the CNIC to enhance patient care

Halifax, Nova Scotia. March 3rd 2020. ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry

Read the Press Release»»

ABK Biomedical Inc. Raises $30M USD in Series B Financing

Halifax, Nova Scotia. April 8th, 2019. ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing…

Read the Press Release»»

Strategic Partnership with the University of Missouri Research Reactor Center (MURR®)

Halifax, Nova Scotia. February 13th, 2019. ABK Biomedical Inc. (ABK) is pleased to announce a multi-year strategic partnership with the University of Missouri Research Reactor Center (MURR®)…

Read the Press Release»»

Our Products

Y90 radioembolization with Eye90 microspheres

Eye90 microspheres™

A novel technology for Y90 radioembolization made with a proprietary, radiopaque glass composition for in-procedure visualization.

Bland embolization with easi-vue embolic microspheres

Easi-Vue™ embolic microspheres

Radiopaque bland embolization product allowing direct visualization at the target site.

Leadership Team

Mike Mangano - President and CEO ABK Biomedical

Michael Mangano

President and CEO

> an accomplished global executive leader with over 25 years’ experience in the medical device industry. 

Gary - Donofrio - Chief Business Officer ABK Biomedical

Gary Donofrio

Chief Business Officer

> extensive marketing and commercialization experience with over 25 years in the medical device field.

Mike Tyson - CFO ABK Biomedical

Mike Tyson

Chief Financial Officer

> over 35 years’ experience in public accounting and leadership positions.

David Dobrowski - VP Clinical Development ABK biomedical

David Dobrowski

VP of Clinical Development and Regulatory Affairs

> an accomplished Life Sciences Executive and Enterprise Leader with over 25 years of pharmaceutical and medical device development experience. 

Bob Abraham - CMO ABK Biomedical

Bob Abraham

Co-Founder and Chief Medical Officer

> Co-founder of ABK Biomedical with more than 20 years as a practicing clinician and interventional radiologist at Nova Scotia Health Authority. 

Marc Gregoire - VP R&D ABK Biomedical

Mark Gregoire

VP R&D and Nuclear Operations

> an accomplished professional mechanical engineer with extensive experience in the nuclear medical products sector.

Anthony Headley - VP Manufacturing ABK Biomedical

Anthony Headley

Vice President, Manufacturing and Facilities

> an accomplished medical device executive with 25 years experience leading and building engineering, manufacturing, and R&D organizations


The ABK Biomedical Team

We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.

ABK Biomedical is an equal opportunity employer offering competitive compensation packages.

ABK's Business Partners

ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.

Investment Partners

Research Partners

Development Partners

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3

T. 902.442.4009


Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. ABK Biomedical inc. products are considered investigational products and are NOT FDA approved for use. Y90 radioembolization

(C) Copyright 2021 - All International Rights Reserved